Drugs / CCX872-B
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02345408 | Feb 2015 → May 2020 | malignant pancreatic neoplasm | Amgen | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03778879 | Aug 2019 | pancreatic adenocarcinoma | Alan Katz | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CCX872-B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03778879 ↗ |
| Action | Inhibit | “inhibiting entry of CCR2+ IM using a small molecule antagonist against CCR2” NCT03778879 ↗ |
| Modality | Small molecule | “using a small molecule antagonist against CCR2” NCT03778879 ↗ |
| Route | Oral | “Tablets (oral administration)” NCT02345408 ↗ |
| Target | CCR2 | “using a small molecule antagonist against CCR2” NCT03778879 ↗ |